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The ATP-binding cassette transporter ABCA1 is essen-
tial for high density lipoprotein (HDL) formation and
considered rate-controlling for reverse cholesterol
transport. Expression of the Abca1 gene is under control
of the liver X receptor (LXR). We have evaluated effects
of LXR activation by the synthetic agonist T0901317 on
hepatic and intestinal cholesterol metabolism in
C57BL/6J and DBA/1 wild-type mice and in ABCA1-defi-
cient DBA/1 mice. In wild-type mice, T0901317 increased
expression of Abca1 in liver and intestine, which was
associated with a 60% rise in HDL. Biliary cholesterol
excretion rose 2.7-fold upon treatment, and fecal neutral
sterol output was increased by 150–300%. Plasma cho-
lesterol levels also increased in treated Abca1/ mice
(120%), but exclusively in very low density lipoprotein-
sized fractions. Despite the absence of HDL, hepatobili-
ary cholesterol output was stimulated upon LXR activa-
tion in Abca1/ mice, leading to a 250% increase in the
biliary cholesterol/phospholipid ratio. Most impor-
tantly, fecal neutral sterol loss was induced to a similar
extent (300%) by the LXR agonist in DBA/1 wild-type
and Abca1/ mice. Expression of Abcg5 and Abcg8, re-
cently implicated in biliary excretion of cholesterol and
its intestinal absorption, was induced in T0901317-
treated mice. Thus, activation of LXR in mice leads to
enhanced hepatobiliary cholesterol secretion and fecal
neutral sterol loss independent of (ABCA1-mediated) el-
evation of HDL and the presence of ABCA1 in liver and
intestine.
Reverse cholesterol transport (RCT)1 or centripetal choles-
terol flux is a key process in maintenance of whole body cho-
lesterol homeostasis (1–6). RCT involves efflux of excess cho-
lesterol from peripheral cells toward nascent high density
lipoprotein (HDL) and its transport to the liver, followed by
hepatic uptake mediated by scavenger receptor class B type I
(SR-BI), biliary secretion in the form of cholesterol or bile salt,
and finally disposal into feces. HDL-mediated RCT is generally
assumed to underlie the well known epidemiological relation-
ship between high HDL cholesterol levels and low risk for
development of atherosclerosis.
Efflux of cholesterol from peripheral cells, including macro-
phages in the vessel wall, is now known to be mediated in part
by the ATP-binding cassette transporter ABCA1 (7–10). Abca1
mRNA is widely distributed throughout the body, with high
expression levels in macrophages, hepatocytes, and enterocytes
(11, 12). This distribution pattern has recently been confirmed
for the ABCA1 protein (13). The role of ABCA1 in hepatocytes
is currently unknown, but may involve formation of pre--HDL
particles (14). In the intestine, ABCA1 has been suggested to be
involved in cholesterol efflux from enterocytes into the lumen,
thereby regulating the efficiency of intestinal cholesterol ab-
sorption (15, 16).
HDL is considered a major source for bile-destined choles-
terol and phospholipid (17, 18). Yet, we have recently demon-
strated that, despite the absence of HDL, hepatobiliary choles-
terol flux and fecal sterol excretion are not affected in Abca1
knockout mice (19). Our results thus questioned whether
ABCA1 has indeed an important role in control of mass choles-
terol transport from the periphery to the liver and suggest that
its major peripheral function is removal of excess cholesterol
from macrophages. Haghpassand et al. (20) showed convinc-
ingly that efflux from macrophages constitutes only a small
fraction of HDL cholesterol.
Several genes involved in control of cholesterol metabolism,
including Abca1, are transcriptionally regulated by the liver X
receptor (LXR) (21–24). Two LXR isoforms have been identi-
fied, LXR (NR1H3) and LXR (NR1H2) (25, 26). Upon stim-
ulation by oxysterols, activated LXR forms a heterodimer with
the retinoid X receptor (RXR, NR2B1), binds to DNA, and
influences gene expression. It has been proposed that a high
dietary cholesterol intake (via subsequent formation of oxy-
sterols) activates LXR, which, in turn, induces expression of
genes involved in cholesterol disposal (27, 28). Because of its
prominent position in controlling cholesterol homeostasis,
pharmacological activation of LXR is considered a promising
approach to raise HDL, to improve RCT, and thereby to prevent
the development of atherosclerosis. Treatment of rodents with
LXR (or retinoid X receptor) agonists indeed results in eleva-
tion of plasma HDL levels (29, 30) and reduced intestinal
cholesterol absorption (23).
In this study, we have investigated the role of ABCA1 in
LXR-controlled pathways of hepatobiliary and fecal cholesterol
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output in mice. For this purpose, wild-type and ABCA1-defi-
cient mice (31) were treated with the synthetic LXR agonist
T0901317 (23, 29). Surprisingly, both T0901317-treated
Abca1/ and wild-type mice showed similarly increased rates
of hepatobiliary cholesterol output and increased fecal sterol
loss independent of (ABCA1-mediated) elevation of plasma
HDL levels and the (putative) role of ABCA1 in intestinal
cholesterol absorption.
EXPERIMENTAL PROCEDURES
Animals—Male C57BL/6J mice (2–3 months old) were purchased
from Harlan (Horst, The Netherlands). Abca1/ mice with a DBA/1
background (6–8 months old) and age-matched DBA/1 wild-type mice
were obtained from IFFA Credo (Saint-Germain-sur-L’Arbresle,
France). Because of the limited supply of homozygous knockout mice,
both male and female mice were used in these experiments. Animals
received standard mouse chow (Hope Farms BV, Woerden, The Neth-
erlands) and water ad libitum.
Experimental Methods—The synthetic LXR agonist T0901317,
kindly provided by Organon BV (Oss, The Netherlands), was solubilized
in Me2SO. This solution was diluted 1:1 with chremophor and further
diluted 1:9 with mannitol/water (5%). Animals received 20 mol of
T0901317/kg/day by gavage at 4 p.m. Control groups were treated with
the solvent only. All animals were housed separately, and feces of
individual mice were collected from days 4 to 5. At day 5, mice were
anesthetized by intraperitoneal injection of Hypnorm (fentanyl/flua-
nisone, 1 ml/kg) and diazepam (10 mg/kg). Bile was collected for 30 min
by cannulation of the gallbladder. During bile collection, body temper-
ature was stabilized using a humidified incubator. At the end of the
collection period, animals were killed by cardiac puncture. Blood was
collected in EDTA-containing tubes. Livers were excised and weighed.
The small intestine was rinsed with cold phosphate-buffered saline and
divided into three equal parts. Parts of both the liver and intestine were
snap-frozen in liquid nitrogen and stored at 80 °C for mRNA isolation
and biochemical analysis. Samples for microscopic evaluation were
frozen in isopentane and stored at 80 °C or fixed in paraformaldehyde
for hematoxylin/eosin and oil red O staining. C57BL/6J mice used for
RNA isolation and lipid analysis only were killed without prior bile
collection. Tissues were immediately removed, snap-frozen in liquid
nitrogen, and manipulated as described below.
Analytical Methods—Bile salts were measured enzymatically (32).
Commercially available kits were used for the determination of free
cholesterol (Wako, Neuss, Germany); total cholesterol, HDL cholesterol,
and triglycerides (Roche Molecular Biochemicals, Mannheim, Ger-
many); and phospholipids and free fatty acids (Wako) in plasma. He-
patic and biliary lipids were extracted according to Bligh and Dyer (33).
Phospholipids in bile and liver were determined as described by
Bo¨ttcher et al. (34). Cholesterol in bile was measured according to
Gamble et al. (35). Hepatic cholesterol and triglyceride contents were
analyzed as described above. Feces were lyophilized, weighed, and
homogenized. Neutral sterols and bile salts were analyzed according to
Arca et al. (36) and Setchell et al. (37), respectively. Pooled plasma
samples from all animals of one group were used for lipoprotein sepa-
ration by fast protein liquid chromatography (FPLC) as described pre-
viously (38).
RNA Isolation and PCR Methods—Total RNA was isolated with
Trizol (Invitrogen) and quantified using Ribogreen (Molecular Probes,
Inc., Eugene, OR). cDNA synthesis was done according to Bloks et al.
(39). For C57BL/6J mice, all three intestinal samples per mouse were
analyzed separately, whereas for DBA/1 and Abca1/ mice, equal
amounts of RNA from the three distinct parts of the small intestine
were pooled prior to reverse transcription. Real-time quantitative PCR
(40) was performed using an Applied Biosystems 7700 sequence detec-
tor according to the manufacturer’s instructions. Primers were obtained
from Invitrogen. Fluorogenic probes, labeled with 6-carboxyfluorescein
and 6-carboxytetramethylrhodamine, were made by Eurogentec (Sera-
ing, Belgium); all sequences are listed in Table I. All expression data
were subsequently standardized for 18 S rRNA, which was analyzed in
separate runs.
Statistics—Statistical analyses were performed using SPSS Version
10.0 for Windows (SPSS Inc., Chicago, IL). Treated and untreated
groups were compared by Student’s t test for large data series of
biochemical parameters and by the Mann-Whitney U test for the re-
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LXR Activation by T0901317 Increases Plasma HDL and
Induces Hepatic Steatosis in C57BL/6J Mice—Treatment with
the LXR agonist T0901317 resulted in profound changes in
plasma and liver lipid homeostasis in C57BL/6J mice, as pre-
viously reported by ourselves (41) and others (23, 29). On the
treatment protocol employed in this study, mice developed
significantly elevated plasma levels of cholesterol, particularly
in the esterified fraction, and phospholipids. HDL cholesterol
was elevated by 59% upon treatment. Administration of
T0901317 increased liver weight by 40% without any change in
body weight. Hepatic total cholesterol content was decreased in
treated mice (15%), partly as a result of a significantly dimin-
ished cholesteryl ester concentration (32%), whereas the con-
centration of phospholipids was not affected. In treated animals,
FIG. 1. Fecal loss of neutral sterols and bile salts of C57BL/6J
mice treated with the LXR agonist T0901317 or its solvent.
C57BL/6J mice were treated with T0901317 (black bars) or solvent only
(white bars) for 4 days (n  10 per group); feces were collected during
the last 24 h of the experiment and analyzed as described under “Ex-
perimental Procedures.” The asterisks indicate significant difference
(Student’s t test, p  0.001).
FIG. 2. mRNA expression levels in the intestines of C57BL/6J
mice treated with the LXR agonist T0901317 or its solvent meas-
ured by real-time PCR. C57BL/6J mice were treated with T0901317
() or solvent only (E) for 4 days (n  four per group); the intestine was
removed, rinsed with cold phosphate-buffered saline, divided into three
equal parts, and analyzed as described under “Experimental Proce-
dures.” All data were standardized for 18 S rRNA. Expression in the
proximal part of the small intestine in animals receiving the solvent
only was set to 1. The asterisks indicate significant difference (Mann-
Whitney U test, p  0.05). A–E, relative expression of Abca1, Abcg5,
Abcg8, Hmgcr, and Acat1, respectively.
TABLE II
Bile flow and biliary secretion rates of C57BL/6J mice treated with
the LXR agonist T0901317 or its solvent
Male C57BL/6J mice (2–3 months old) were treated with the LXR
agonist T0901317 or solvent only as described under “Experimental
Procedures” (n  six per group). Bile was collected for 30 min. Values
represent means  S.D.
Control T0901317
Bile flow (l/min/100 g body
weight)
8.2  2.8 7.8  2.6
Bile salts (nmol/min/100 g
body weight)
584  229 477  200
Cholesterol (nmol/min/100 g
body weight)
3.8  1.4 10.3  3.1a
Phospholipids (nmol/min/100 g
body weight)
52.7  10.8 44.2  9.7
Cholesterol/phospholipid ratio 0.07  0.03 0.23  0.04b
a Indicates significant difference (Mann-Whitney U test, p  0.05).
b Indicates significant difference (Mann-Whitney U test, p  0.001).
TABLE III
mRNA expression levels in liver tissue of C57BL/6J mice treated with
the LXR agonist T0901317 or its solvent measured by real-time
reverse transcription-PCR
Male C57BL/6J mice (2–3 months old) were treated with the LXR
agonist T0901317 or solvent only as described under “Experimental
Procedures” (n  four per group). Quantitative real-time PCR was
performed as described under “Experimental Procedures” with the
primers and probes given in Table I. All data were standardized for 18
S rRNA. Expression in control mice was set to 1.00. Values represent
means  S.D.
mRNA Control T0901317
Srebp1a 1.00  0.18 1.22  0.06
Srebp1c 1.00  0.15 2.64  0.54a
Srebp2 1.00  0.17 1.00  0.06
LXR 1.00  0.09 0.84  0.11
Hmgcr 1.00  0.10 1.55  0.36a
Cyp7a1 1.00  0.42 1.45  0.74
Cyp27 1.00  0.16 0.94  0.08
Acat2 1.00  0.12 1.24  0.27
Abca1 1.00  0.55 2.38  0.96a
Abcg5 1.00  0.42 2.81  1.19a
Abcg8 1.00  0.56 1.54  0.51
Bsep 1.00  0.18 1.01  0.06
Mdr2 1.00  0.10 1.13  0.17
Ntcp 1.00  0.04 0.97  0.10
Oatp1 1.00  0.41 0.63  0.09
a Indicates significant difference (Mann-Whitney U test, p  0.05).
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we found a 8-fold increase in hepatic triglyceride content, in
accordance with recently published studies (30). Histologically,
these animals presented with profound hepatic fat deposits, but
no signs of liver damage were noticed (data not shown).
LXR Activation by T0901317 Induces Biliary Hypersecretion
of Cholesterol in C57BL/6J Mice—Bile flow was unaffected by
T0901317 treatment when calculated on the basis of body
weight (Table II). Biliary cholesterol output was 2.7-fold higher
upon treatment, whereas biliary bile salt and phospholipid
output was not affected. As a consequence, the ratio of choles-
terol to phospholipids increased from 0.07 to 0.23 upon treat-
ment, indicative of uncoupling of biliary cholesterol from phos-
pholipid secretion.
Gene expression profiles of key regulatory, metabolic, and
transporter-encoding genes involved in hepatic cholesterol me-
tabolism were analyzed by real-time PCR (Table III). As ex-
pected (42, 43), the gene encoding sterol regulatory element-
binding protein 1c (Srebp1c) was the only regulatory gene with
a modified expression (2.6-fold up) upon T0901317 treatment.
This predicted increase is indicative of the overall stimulatory
action of the agonist on hepatic gene expression, also supported
by an 5-fold increase in expression levels of the LXR target
gene Lpl encoding lipoprotein lipase (data not shown). The
gene encoding 3-hydroxy-3-methylglutaryl-coenzyme A reduc-
tase (Hmgcr), the key enzyme in cholesterol synthesis, was
up-regulated by 55%, whereas the 45% up-regulation of the bile
salt synthesis gene Cyp7a1 did not reach statistical signifi-
cance. T0901317 treatment increased expression of Abca1 and
Abcg5 2.4- and 2.8-fold, respectively; expression of hepatic
Abcg8 showed a high variation in its expression levels. Expres-
sion of transporters involved in bile salt uptake (Ntcp (Na/
taurocholate-cotransporting polypeptide) and Oatp1 (organic
anion-transporting polypeptide-1)) and secretion (Bsep (bile
salt export pump)) and in phospholipid secretion (Mdr2 (mul-
tidrug resistance P-glycoprotein-2)) remained unaffected.
LXR Activation by T0901317 Accelerates Fecal Sterol Loss in
C57BL/6J Mice—Fecal bile salt loss was increased by 84%
upon activation of LXR with T0901317 (Fig. 1), reflecting in-
creased hepatic bile salt synthesis. In addition, neutral sterol
output was enhanced by 187% in T0901317-treated mice. In-
creased expression of Abca1 in the intestine has been proposed
to reduce the efficacy of cholesterol (re)absorption and hence to
enhance fecal cholesterol disposal (23). Indeed, treatment of
mice with the LXR agonist T0901317 resulted in an 3-fold
increase in Abca1 mRNA abundance along the entire length of
the small intestine (Fig. 2A). Likewise, expression of Abcg5 and
Abcg8, recently implicated in control of cholesterol absorption
(44–46), was induced in treated animals, albeit less pro-
nounced than that of Abca1 (Fig. 2, B and C). In contrast,
mRNA levels of Hmgcr and Acat1 (encoding acyl-coenzyme
A:cholesterol acyltransferase-1), indicative of intestinal choles-
terol synthesis and cholesterol esterification, respectively, were
similar in treated and control animals (Fig. 2, D and E). No
changes in intestinal morphology were noted upon microscopic
examination of hematoxylin/eosin- and oil red O-stained sec-
tions (data not shown).
To elucidate the specific role of ABCA1 in the observed LXR-
mediated stimulation of cholesterol disposal in mice, we sub-
sequently conducted a series of similar experiments in
Abca1/ mice and adequate wild-type controls on a DBA/1
background. Both male and female mice were used in these
studies; no specific gender effects on the parameters studied
were noted unless otherwise stated. Therefore, outcome is, in
most cases, presented as average values per group.
LXR Activation by T0901317 Increases Cholesterol in Very
Low Density Lipoprotein (VLDL)-sized Fractions in Abca1/
Mice—Upon treatment with T0901317, plasma concentrations
of free cholesterol were increased in both Abca1/ and DBA/1
wild-type mice (Table IV). Cholesteryl ester concentrations
were not significantly affected, resulting in an increase in total
cholesterol in Abca1/ mice only. Both plasma phospholipid
and triglyceride levels were not significantly changed upon
T0901317-mediated activation of LXR in DBA/1 mice. FPLC
separation of plasma lipoproteins revealed that, as anticipated,
the increase in plasma cholesterol in wild-type mice was in the
HDL-sized lipoprotein fraction. Fig. 3 illustrates the lipopro-
tein pattern in T0901317-treated wild-type and Abca1/ mice.
Upon LXR activation, wild-type mice showed elevated choles-
terol concentrations in the HDL-sized fractions, whereas
Abca1/ mice showed increased cholesterol concentrations in
the VLDL-sized fractions.
Hepatobiliary Cholesterol Secretion Is Increased upon
T0901317 Treatment in Both Wild-type and Abca1/
Mice—As shown in Table V, treatment with T0901317 did not
change bile flow in wild-type or Abca1/ mice. Bile salt secre-
tion remained unchanged in wild-type mice, but slightly de-
creased in T0901317-treated Abca1/ mice. Phospholipid out-
put rates were not altered in Abca1/ mice and were
moderately lowered in wild-type mice upon LXR activation.
Expression of genes involved in hepatic cholesterol metabolism
and of ATP-binding cassette transporters known to be involved
FIG. 3. FPLC analysis of plasma cholesterol of DBA/1 and
Abca1/ mice treated with the LXR agonist T0901317. DBA/1
wild-type mice (E) and Abca1/ mice () were treated with T0901317
for 4 days (n  five per group). Blood was collected via cardiac puncture
and pooled before FPLC analysis. Analysis was performed as described
under “Experimental Procedures.” IDL, intermediate density lipopro-
tein; LDL, low density lipoprotein.
TABLE IV
Plasma lipid levels in DBA/1 wild-type and Abca1/ mice treated with the LXR agonist T0901317 or its solvent
Male and female DBA/1 wild-type and Abca1/ mice (6–8 months old) were treated with the LXR agonist T0901317 or solvent only as described
under “Experimental Procedures” (n  five to six per group). Blood was collected by cardiac puncture. Values represent means  S.D.
Wild-type Abca1/
Control T0901317 Control T0901317
Total cholesterol (mM) 1.12  0.55 1.64  0.69 0.50  0.30 1.11  0.33a
Free cholesterol (mM) 0.35  0.14 0.62  0.10a 0.29  0.08 0.72  0.25a
Cholesteryl ester (mM) 0.77  0.42 1.02  0.69 0.21  0.28 0.39  0.14
Phospholipids (mM) 1.26  0.61 2.07  1.28 0.75  0.43 1.34  0.28
Triglycerides (mM) 0.73  0.33 0.93  0.28 0.83  0.38 1.88  1.39
a Indicates significant difference (Mann-Whitney U test, p  0.05).
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in bile formation (i.e. Bsep and Mdr2) was not affected by
ABCA1 deficiency or LXR activation (Table VI). Biliary choles-
terol secretion was markedly increased in T0901317-treated
DBA/1 mice and, despite the absence of HDL, to the same
extent in treated Abca1/ mice. In both strains, a 3 times
higher cholesterol/phospholipid ratio was found in bile, indica-
tive of cholesterol hypersecretion induced by LXR activation
that is independent of ABCA1 functioning.
Fecal Neutral Sterol Excretion Is Stimulated by LXR Activa-
tion in the Absence of ABCA1—Fecal sterol loss during the final
24 h of the experiment is shown in Fig. 4. Fecal bile salt output
was similar in DBA/1 wild-type and Abca1/ mice both under
control conditions and upon LXR stimulation (Fig. 4, upper
panel). As expected, neutral sterol loss in wild-type mice was
dramatically increased upon treatment (Fig. 4, lower panel).
Surprisingly, Abca1/ mice showed a very similar response
upon LXR activation, i.e. a significantly higher neutral sterol
output.
The entry of cholesterol into the intestinal lumen consists of
at least three components: delivery via bile; dietary intake; and
direct intestinal secretion by enterocytes into the lumen, in-
cluding shedding of cells. The rate of fecal cholesterol excretion
(loss) is determined by the cumulative rate of cholesterol entry
and the rate of (re)absorption of luminal cholesterol. From
earlier studies (38), we know that dietary intake is 4 mol/
100 g/day, which, under basal conditions, is similar to the
biliary cholesterol flux in C57BL/6J mice. The basal rate of
fecal cholesterol excretion in C57BL/6J mice is 17 mol/100
g/day, which is higher than the sum of dietary and biliary
cholesterol influx into the intestine. By inference, at least
50% of fecal cholesterol must originate in the intestine. As-
suming no major effect of T0901317 treatment on dietary cho-
lesterol intake, the treatment did not affect the relative contri-
bution of cholesterol from the intestine to the amount of
cholesterol excretion via feces, again at least 50%. This im-
plies, however, that T0901317 treatment significantly in-
creased the absolute amount of cholesterol in feces originating
in the intestine. In DBA/1 wild-type and Abca1/ mice under
FIG. 4. Fecal loss of neutral sterols and bile salts of DBA/1 and
Abca1/ mice treated with the LXR agonist T0901317 or its
solvent. DBA/1 wild-type and Abca1/ mice were treated with
T0901317 (black bars) or solvent only (white bars) for 4 days (d) (n 
five per group). Feces were collected for the last 24 h of the experiment
and analyzed as described under “Experimental Procedures.” The as-
terisks indicate significant difference (Mann-Whitney U test, p  0.05).
TABLE V
Bile flow and biliary secretion rates in DBA/1 wild-type and Abca1/ mice treated with the LXR agonist T0901317 or its solvent
Male and female DBA/1 wild-type and Abca1/ mice (6–8 months old) were treated with the LXR agonist T0901317 or solvent only as described
under “Experimental Procedures” (n  five to six per group). Bile was cannulated for 30 min. Values represent means  S.D.
Wild-type Abca1/
Control T0901317 Control T0901317
Bile flow (l/min/100 g body weight) 7.2  0.9 7.4  1.2 7.8  1.6 7.9  1.8
Bile salts (nmol/min/100 g body weight) 392  68 307  119 472  213 251  120a
Cholesterol (nmol/min/100 g body weight) 8.0  1.1 17.0  3.2a 8.4  2.5 19.5  7.5a
Phospholipids (nmol/min/100 g body weight) 63.1  7.0 38.1  7.7a 67.6  16.2 48.6  22.3
Cholesterol/phospholipid ratio 0.13  0.02 0.46  0.13a 0.12  0.03 0.42  0.08a
a Indicates significant difference (Mann-Whitney U test, p  0.05).
TABLE VI
mRNA expression levels in liver tissue of DBA/1 wild-type and Abca1/ mice treated with the LXR agonist T0901317 or its solvent
measured by real-time reverse transcription-PCR
Male and female DBA/1 wild-type and Abca1/ mice (6–8 months old) were treated with the LXR agonist T0901317 or solvent only as described
under “Experimental Procedures” (n  five per group). cDNA synthesis and real-time PCR were performed as described under “Experimental
Procedures” with the primers and probes given in Table I. All data were standardized for 18 S rRNA. Expression in wild-type mice receiving solvent
only was set to 1.00. Values represent means  S.D.
mRNA
Wild-type Abca1/
Control T0901317 Control T0901317
Srebp1c 1.00  0.31 2.04  1.22 1.17  0.49 2.49  0.78a
Hmgcr 1.00  0.25 0.90  0.36 0.60  0.22 1.18  0.43a
Cyp7a1 1.00  0.36 0.60  0.26 0.92  0.40 0.46  0.20
SR-BI 1.00  0.14 0.73  0.19a 0.81  0.20 0.69  0.12
Abca1 1.00  0.41 0.80  0.38 0.53  0.17 0.52  0.08
Abcg5 1.00  0.14 1.75  0.85 0.75  0.28 1.91  0.67a
Abcg8 1.00  0.16 1.65  0.68 0.81  0.16 1.51  0.48a
Bsep 1.00  0.14 1.07  0.45 0.86  0.16 1.02  0.40
Mdr2 1.00  0.27 0.83  0.21 0.88  0.16 0.76  0.14
a Indicates significant difference (Mann-Whitney U test, p  0.05).
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basal conditions, the sums of dietary (assumed) and biliary
cholesterol influx into the intestine were higher than the fecal
rate of cholesterol excretion, indicating net cholesterol absorp-
tion by the intestine. After T0901317 treatment, however, the
sum of biliary and dietary (assumed) cholesterol influx into the
intestine was lower than the fecal rate of cholesterol excretion,
implying that the net intestinal cholesterol flux had shifted
from absorption from the lumen to excretion into the lumen
(data not shown).
The absence of any effect of genotype or treatment on intes-
tinal expression of Hmgcr indicates that changes in fecal neu-
tral sterol excretion are unlikely due to effects on intestinal
cholesterol synthesis (Table VII). Expression of Abca1 was
clearly induced in the intestines of wild-type mice after treat-
ment with T0901317. The intestinal expression of Abcg5 and
Abcg8 was similar in wild-type and Abca1/ mice and, in both
strains, up-regulated upon LXR activation. Due to high varia-
tion, there was no significant increase in Abcg5 mRNA levels in
the wild-type mice. This high variation was, at least partly,
caused by less pronounced induction in male animals. In wild-
type mice, expression of Acat1 and SR-BI also increased signif-
icantly. This effect was less pronounced in Abca1/ mice.
DISCUSSION
Activation of the nuclear receptor LXR influences multiple
steps involved in maintenance of cholesterol homeostasis, par-
ticularly by inducing expression of genes that control key steps
in removal of excess cholesterol from the body. It has been
postulated that LXR agonists may combine three potentially
anti-atherogenic effects, i.e. increased efflux from peripheral
tissues toward HDL by up-regulation of ABCA1 and ABCG1,
increased catabolism of cholesterol by up-regulation of bile salt
synthesis, and inhibition of dietary cholesterol absorption via
up-regulation of intestinal cholesterol transporters like
ABCA1, ABCG5, and ABCG8 (15, 16). The present study dem-
onstrated that short-term administration of the LXR agonist
T0901317 elevates plasma HDL levels in wild-type mice, both
of C57BL/6J and DBA/1 backgrounds, as previously described
(29, 30). This was accompanied by a marked hypersecretion of
cholesterol into bile and a strongly increased fecal excretion of
neutral sterols. Biliary secretion of phospholipids and, in the
wild-type mice, also of bile salts remained largely unaffected.
Hence, LXR activation fully uncoupled cholesterol from other
biliary lipids. Surprisingly, increased hepatobiliary and fecal
cholesterol disposal was found to be totally independent of
ABCA1-mediated HDL formation and the (putative) contribu-
tion of ABCA1 to the control of intestinal cholesterol absorption
because the effects of LXR activation on these parameters were
indistinguishable between DBA/1 wild-type and Abca1/
mice. Moreover, the results of this study strongly indicate that
pharmacological LXR activation stimulates direct efflux of cho-
lesterol from the intestinal epithelium into the lumen. Based
on the assumption that dietary intake of cholesterol was iden-
tical in all groups and an estimate of 24 h of biliary cholesterol
excretion, this efflux was calculated as the difference between
dietary and biliary input minus fecal output. LXR activation
greatly increased this flux. From our data, however, we cannot
draw conclusions concerning the relative contributions of de-
creased absorption, increased direct sterol excretion by intes-
tinal cells, and accelerated shedding of enterocytes to this net
loss of sterols. There were no indications of a compensatory
increase in intestinal cholesterol synthesis because Hmgcr ex-
pression remained unaffected along the length of the small
intestine. Independent of the mechanism, this finding delin-
eates the important role of the intestine in cholesterol homeo-
stasis, as suggested by us previously (19, 38, 47), and that the
presence of ABCA1 is not required to fulfill this role. In line
with the proposed role of the ATP-binding cassette half-trans-
porters ABCG5 and ABCG8 in cholesterol efflux toward the
intestinal lumen (44, 45) and the consistently induced expres-
sion of these genes in intestines of LXR agonist-treated mice, it
is tempting to speculate that these half-transporters have a
crucial role in LXR-induced changes in intestinal cholesterol
metabolism.
The classical view of RCT (1) predicts that, under steady-
state conditions, all cholesterol synthesized in peripheral or-
gans is eventually transported by HDL to the liver for excretion
into bile, followed by its disposal via feces. ABCA1 is considered
a crucial factor in this process because the absence of a func-
tional protein in Tangier disease (7–9) and in Abca1/ mice
(31) is associated with a complete lack of HDL. The validity of
the RCT concept to explain mass cholesterol flux from the
periphery to the liver has been questioned by a series of studies
in mice showing that the magnitude of RCT (or “centripetal
cholesterol flux”) is not determined by plasma HDL levels
(48–53) and is not affected by stimulation of individual key
steps in the process, such as cholesterol efflux from peripheral
tissues, SR-BI-mediated uptake of HDL cholesterol by the
liver, and conversion of cholesterol into bile salts (54). In addi-
tion, we have recently shown that the absence of HDL due to
ABCA1 deficiency does not alter hepatic cholesterol synthesis,
which would be anticipated if HDL accommodates a quantita-
tively important cholesterol flux toward the liver, and does not
affect biliary cholesterol excretion and fecal sterol loss (19).
These observations, together with the fact that macrophages
contribute only modestly to HDL cholesterol (20), indicate that
the relevance of ABCA1 and high HDL in protection from
TABLE VII
mRNA expression levels in intestines of DBA/1 wild-type and Abca1/ mice treated with the LXR agonist T0901317 or its solvent
measured by real-time reverse transcription-PCR
Male and female DBA/1 wild-type and Abca1/ mice (6–8 months old) were treated with the LXR agonist T0901317 or solvent only as described
under “Experimental Procedures” (n five per group). RNA was isolated from three parts of the small intestine; equal amounts of RNA were pooled
for cDNA synthesis and analyzed as described under “Experimental Procedures” with the primers and probes given in Table I. All data were
standardized for 18 S rRNA. Expression in wild-type mice receiving solvent only was set to 1.00. Values represent means  S.D.
mRNA
Wild-type Abca1/
Control T0901317 Control T0901317
Hmgcr 1.00  0.13 0.98  0.16 1.12  0.30 0.87  0.24
Acat1 1.00  0.18 1.84  0.49a 1.19  0.61 1.47  0.55
Acat2 1.00  0.19 1.14  0.29 1.21  0.60 1.01  0.22
Abca1 1.00  0.35 2.59  1.16a 0.42  0.12 1.26  0.40a
Abcg5 1.00  0.09 2.02  0.31a 0.94  0.16 1.72  0.48a
Abcg8 1.00  0.12 1.84  0.33 1.08  0.33 1.90  0.53a
SR-BI 1.00  0.20 2.31  0.89a 1.47  0.57 1.76  0.47
a Indicates significant difference (Mann-Whitney U test, p 0.05). For Abca1,40% of the remaining, putatively inactive mRNA was detectable
in Abca1/ mice, as the PCR primers are located outside the deleted exons (11, 31).
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atherosclerosis is related to events at the level of the vessel
wall rather than to stimulation of mass cholesterol flux. This,
in turn, implies that the absence of HDL in patients with
Tangier disease and Abca1/ mice is not due to the absence of
the protein in macrophages. Because specific overexpression of
ABCA1 in hepatocytes and macrophages of Abca1/ mice us-
ing an adenoviral construct driven by the Apoe promoter nor-
malizes plasma HDL (14), it is tempting to speculate that
hepatic ABCA1 has a role in formation of nascent HDL parti-
cles. Thus, it is highly likely that elevated HDL levels in
T0901317-treated mice are attributable to increased hepatic
ABCA1 expression and function. Elevated VLDL cholesterol in
treated Abca1/ mice may be due to enhanced formation of
VLDL particles by the liver. Recent data from our laboratory
show that LXR activation strongly promotes the production of
large, triglyceride-rich VLDL particles by the liver in wild-type
mice (41). Whether or not there are qualitative or quantitative
differences in this respect between wild-type and Abca1/
mice remains to be established.
There are data to indicate that HDL cholesterol is an impor-
tant source for both biliary cholesterol and bile salt synthesis
(17, 18). The similar increase in biliary cholesterol excretion in
Abca1/ mice and their controls upon LXR activation shows,
at least, that other sources are able to fully compensate for the
lack of HDL cholesterol in Abca1/ mice. As hepatic cho-
lesteryl ester concentrations were diminished by 50–85% in
treated mice independently of the presence of ABCA1, part of
the excess biliary cholesterol may have been derived from he-
patic stores. Expression of Hmgcr was slightly increased in
T0901317-treated mice, indicating that a compensatory in-
crease in synthesis also may contribute. Despite the fact that
Cyp7a1 has been identified as a bona fide LXR target gene in
vitro (55), we observed only a modest (C57BL/6J mice) or no
(DBA/1 mice) increase in fecal bile salt secretion upon LXR
activation, indicating limited effects on total bile salt synthesis.
Accordingly, no significant effects on Cyp7a1 expression levels
were found. The fact that, in contrast to other reports (23, 29,
43), we did not find an induction of Cyp7a1 expression upon
T0901317 administration is probably related to differences in
treatment protocols (see below). It has been known for 10
years that Cyp7a1 mRNA is relatively unstable, putatively
related to the circadian rhythm of its expression (56). We there-
fore might have missed the LXR-induced peak expression
measured by others. In any case, our data demonstrate that
ABCA1-dependent HDL formation is dispensable for biliary
routing of cholesterol both as free cholesterol and after conver-
sion to bile salts.
Interestingly, LXR activation by T0901317 stimulated hepa-
tobiliary cholesterol excretion without influencing biliary phos-
pholipid excretion. The latter is in accordance with unaltered
Mdr2 expression upon LXR activation. Biliary bile salt secre-
tion, which constitutes a major driving force for biliary choles-
terol and phospholipid secretion (57), was either not affected or
even slightly reduced in treated animals. Consequently, LXR
activation leads to cholesterol hypersecretion into bile, as illus-
trated by the 3–4-fold increase in the biliary cholesterol/phos-
pholipid ratio in all T0901317-treated groups of mice. This
suggests LXR-mediated up-regulation of a specific process/
transporter responsible for cholesterol disposal into bile. It has
been suggested that ABCG5/ABCG8, ATP-binding cassette
half-transporters defective in -sitosterolemia (44, 45), may
have a role in this process (15, 16). However, direct evidence for
this role is still lacking. As recently reported (46) and confirmed
in this study, expression of Abcg5 and Abcg8 is indeed induced
in livers of LXR-treated mice. In a recent study, we found a
relationship between rates of biliary cholesterol excretion and
hepatic Abcg5/Abcg8 expression in different mouse models of
biliary cholesterol hypersecretion.2 However, there are also
models of cholesterol hypersecretion, most notably the diosge-
nin-fed mouse, in which Abcg5/Abcg8 expression remains un-
affected. Thus, direct proof for a role of these transporters in
LXR-induced cholesterol hypersecretion will have to await
studies in Abcg5/Abcg8 knockout mice.
It has previously been reported that, besides its effects on
genes involved in cholesterol transport, LXR activation also
affects fatty acid metabolism by both SREBP1c-dependent (42)
and -independent (30) mechanisms and causes hepatic steato-
sis (29). We did find dramatic increases in hepatic triglyceride
content upon T0901317 treatment in all groups, including the
Abca1/ mice, at least partially accounting for the increases in
liver weight/body weight ratios. Overall gene expression pat-
terns were also similar to results reported by other groups (23,
29, 30, 43), although generally less pronounced induction upon
T0901317 treatment was observed. However, for some genes
(e.g. Lpl and phospholipid transfer protein), we did find high
levels of induction (41). The modest increase in the other genes
may be caused by a longer period of time between last dosage of
the agonist and tissue sampling in our experiments or by dif-
ferent application modes (gavage versus diet). From the differ-
ences between C57BL/6J and DBA/1 wild-type mice and from
quantitative differences between other studies (23, 29, 30, 43),
it can furthermore be concluded that strain-specific factors may
also be involved in reported differences in gene expression
patterns upon LXR activation.
Because of its prominent position in controlling cholesterol
homeostasis, pharmacological activation of LXR is currently
being widely discussed as a promising tool to raise HDL, to
improve RCT, and therefore to inhibit or prevent the develop-
ment of atherosclerosis. In this study, we demonstrated that
LXR activation by T0901317 leads to similarly increased rates
of hepatobiliary cholesterol output and increased fecal sterol
loss in wild-type and Abca1/ mice. The underlying LXR-de-
pendent mechanism is thus independent of (ABCA1-mediated)
elevation of plasma HDL levels and the (putative) role of
ABCA1 in intestinal cholesterol absorption. In addition, LXR
activation is associated with stimulation of net cholesterol loss
via the intestine, indicating the presence of additional path-
ways for direct removal of cholesterol from the body.
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